Investigational Drug Information for TL-895
✉ Email this page to a colleague
What is the drug development status for TL-895?
TL-895 is an investigational drug.
There have been 7 clinical trials for TL-895.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 22nd 2020.
The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Lymphoma, Mantle-Cell. The leading clinical trial sponsors are Telios Pharma, Inc., Kartos Therapeutics, Inc., and EMD Serono Research & Development Institute, Inc.
There are twelve US patents protecting this investigational drug and seventy-four international patents.
Summary for TL-895
| US Patents | 12 |
| International Patents | 74 |
| US Patent Applications | 39 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2020-10-22) |
| Vendors | 24 |
Recent Clinical Trials for TL-895
| Title | Sponsor | Phase |
|---|---|---|
| Phase 1b/2 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Telios Pharma, Inc. | Phase 1/Phase 2 |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | Kartos Therapeutics, Inc. | Phase 2 |
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Kartos Therapeutics, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for TL-895
Top disease conditions for TL-895
Top clinical trial sponsors for TL-895
US Patents for TL-895
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TL-895 | ⤷ Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Start Trial |
| TL-895 | ⤷ Start Trial | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Start Trial |
| TL-895 | ⤷ Start Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TL-895
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TL-895 | Australia | AU2012267491 | 2031-06-10 | ⤷ Start Trial |
| TL-895 | Australia | AU2017235978 | 2031-06-10 | ⤷ Start Trial |
| TL-895 | Brazil | BR112013030442 | 2031-06-10 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
